BioCryst Pharmaceuticals BCRX Deferred Foreign Income Tax Expense Benefit
Deferred Foreign Income Tax Expense Benefit at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredForeignIncomeTaxExpenseBenefit.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's deferred foreign income tax expense benefit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's deferred foreign income tax expense benefit?
- BioCryst Pharmaceuticals (BCRX) reported deferred foreign income tax expense benefit of -$257K in Q4 2025.
- How has BioCryst Pharmaceuticals's deferred foreign income tax expense benefit changed year-over-year?
- BioCryst Pharmaceuticals's deferred foreign income tax expense benefit decreased by 137.4% year-over-year, from -$108.25K to -$257K.
- What does deferred foreign income tax expense benefit mean?
- Reflects the change in deferred tax assets and liabilities arising from foreign jurisdictions due to temporary differences in tax and financial reporting. It provides insight into the company's future tax liabilities or benefits expected in international markets where it operates.